Emerging Company Profile: Chinese siRNA Specialist Sirius All In On Cardiovascular Disease
Potential Once-Yearly Regimen
Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.
You may also be interested in...
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
The German group’s fibro-inflammatory deal with Kyowa Kirin has come in the same week as a new oncology collaboration with partner 3T and a liver disease alliance with China’s Ribo.
Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.